Biophytis Announces Unanimous Approval in General Meeting

Biophytis SA, a clinical-stage biotechnology firm focusing on age-related diseases, has announced the successful approval of all resolutions during its Combined General Meeting held on April 2, 2024. The Paris, France, and Cambridge, Massachusetts-based company reported that a quorum of nearly 30% of shareholders was achieved, allowing for the meeting to proceed as planned.

The adopted resolutions included several key financial delegations, which the company views as essential for its ongoing and future operations. The detailed results of these votes have been made available on the Biophytis website for public viewing. This unanimous approval by the shareholders highlights the strong support for the company’s management and strategic direction.

Biophytis specializes in the development of drug candidates for a range of age-related diseases, including muscular and respiratory conditions. Its lead drug candidate, RuvembriTM, is being developed for sarcopenia in phase 3 and for Duchenne muscular dystrophy, with a Covid-19 phase 2-3 trial also completed. The company's shares are traded on the Euronext Growth Paris and Nasdaq Capital Market.